- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05368064
Cleidocranial Dysplasia (CCD): From Genotype to Phenotype and Considerations for Care
Cleidocranial Dysplasia (CCD) is a rare, autosomal dominant disorder characterized by dysplasia of bones and teeth. Given the rarity of this condition (prevalence of 1 in 1,000,000), the variable phenotype and lack of correlation to specific genotypes, coordinated clinical research is needed to better understand CCD. The purpose of this project is to: investigate the genetic makeup and phenotypic expression of CCD, understand the quality of life for patients with this diagnosis, and further identify the multidimensional healthcare needs of these patients. Participation involves completion of a survey to ascertain medical history and quality of life, a physical exam and research whole exome sequencing from a blood or saliva sample. The goal of this research is to elucidate critical pathways in skeletal and dental development and improve quality of life for CCD patients through the standardization and optimization of timely diagnosis and multidisciplinary care.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
patients with clinical or molecular diagnosis of CCD
Description
Inclusion Criteria:
- Patient has molecular or clinical diagnosis of CCD
- Caregiver or parent of patient with CCD.
Exclusion Criteria:
- Patient does not have CCD
- Patient over 18 but cannot consent for themselves
- Not fluent in English.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: CROSS_SECTIONAL
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence of RUNX2 mutation
Time Frame: 3 years
|
identify the RUNX2 mutation in each participant |
3 years
|
|
Phenotypic description of each patient with CCD
Time Frame: 3 years
|
Physical exam, dental exam, medical history collection |
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient financial stress quality of life score as assessed by the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT)
Time Frame: 3 years
|
Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) will be used to assess financial quality of life stress; numeric response 0-4; Score range 0-44 with higher scores indicating better Financial Well-Being. |
3 years
|
|
Patient-reported health-related quality of life as assessed by the FANLTC (Functional Assessment of Non-life-threatening conditions)
Time Frame: 3 years
|
FAN LTC (0 = not al all, 4 = very much) |
3 years
|
|
Patient-reported health-related quality of life
Time Frame: 3 years
|
Quality of Life questionnaire (7 = delighted, 1 = terrible) |
3 years
|
|
Caregiver-reported quality of life of caregivers for patients with CCD
Time Frame: 3 years
|
COST-FACIT (variable quality of numeric response 0-4); FAN LTC (0 = not at all, 4 = very much) |
3 years
|
|
Whole exome sequencing if RUNX2 molecular analysis negative for pathogenic variant
Time Frame: 3 years
|
sequencing |
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ilana Ickow, DMD, MS, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Craniofacial Abnormalities
- Musculoskeletal Abnormalities
- Congenital Abnormalities
- Osteochondrodysplasias
- Bone Diseases, Developmental
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Cleidocranial Dysplasia
- Health Services Administration
- Quality of Health Care
- Outcome Assessment, Health Care
- Outcome and Process Assessment, Health Care
- Watchful Waiting
Other Study ID Numbers
- IRB00246592
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.